Shopping Cart
- Remove All
- Your shopping cart is currently empty
Leu-AMS, a leucine analogue and potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM, exhibits cytotoxic effects in both cancer and normal cells and hampers bacterial growth. It specifically inhibits LRS's catalytic activity without impacting the leucine-induced activation of mTORC1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Leu-AMS, a leucine analogue and potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM, exhibits cytotoxic effects in both cancer and normal cells and hampers bacterial growth. It specifically inhibits LRS's catalytic activity without impacting the leucine-induced activation of mTORC1. |
Targets&IC50 | LRS:22.34 nM |
In vitro | Leu-AMS does not affect S6 kinase (S6K) phosphorylation at all.?Leu-AMS inhibits the catalytic activity of LRS but does not affect the leucine-induced mTORC1 activation[1].Leu-AMS is proved to be a potent inhibitor of Leucyl-tRNA Synthetase (LRS) with an IC50 value of 22.34 nM.?Leu-AMS is highly cytotoxic in both cancer cells and normal cells. |
Molecular Weight | 459.48 |
Formula | C16H25N7O7S |
Cas No. | 288591-93-5 |
Relative Density. | 1.83 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 49.17 mg/mL (107.01 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.